Dosing and uses of Austedo (deutetrabenazine)
Huntington Disease
Pending FDA approval for treatment of chorea associated with Huntington disease
Pharmacology of Austedo (deutetrabenazine)
Mechanism of action
Oral vesicular monoamine transporter-2 (VMAT-2) inhibitor, resulting in decreased uptake of monoamines (eg, dopamine, serotonin, norepinephrine, histamine) into synaptic vesicles and depletion of monoamine stores from nerve terminals
